Check Point Earnings Preview: Cautious Positioning After a Big Rally
Produced automatically from ORTEX data and published under the ORTEX News editorial standards set by Peter Hillerberg, Editor, ORTEX News. How we publish
CHKP reports Q3 results on October 30, arriving into that print on the back of an 18% rise over the past month but with options traders more defensive than they have been all year.
The clearest pre-earnings signal is in the options market. The put/call ratio has climbed to 0.46, more than two standard deviations above its 20-day average of 0.42, putting it at the most defensive reading in the past year. That shift has come entirely in the final week of October, as the stock pulled back 2.9% on October 28 after its strong monthly run to $155.22. The borrow market tells a different story: availability is generous at roughly 820% of short interest, cost to borrow has edged down to 0.43%, and short interest has risen only modestly, up around 3.8% over the past week to roughly 6.1 million shares. There is no meaningful squeeze pressure and no sign that a large conviction short is being built here.
The analyst community is broadly on the sidelines. Every recent rating in the run-up to this print is a Neutral or equivalent, with targets clustering in the $130 to $150 range. Mizuho raised its target to $145 from $135 in mid-October, but that still sits below the current price of $155. The consensus mean target of $149 is now below where the stock trades, a gap that has widened as CHKP outpaced most peers over the past month. The fundamental debate is genuine: the bull case rests on durable recurring revenue, a 5% price increase executed in January, subscription security revenue growing at 11% in Q1, and a valuation that looks undemanding relative to peers at roughly 4.3x EV/NTM recurring revenue. The bear case points to a 2.9% decline in product revenue in Q1, a go-to-market reorganisation that management itself flagged as delaying pipeline generation, and full-year revenue guidance cut by roughly $80 million, all in the product line. Goldman Sachs cut its target to $150 from $168 after the last print in August, the most notable downward move from a major firm in the past three months.
The ownership picture adds one noteworthy data point. Founder Gil Shwed filed a Schedule 13G/A on October 26, showing his stake at 26.2% of shares, up from 25.5% at the prior filing. Massachusetts Financial Services has also been adding, lifting its holding to 7.4% from 5.7%. Acadian Asset Management more than doubled its position in the most recent quarter. Against that, Norges Bank Investment Management cut its holding by roughly 2.6 million shares in the period ending June 30. The insider register shows only one open-market trade of note: the Chief Product Officer sold 3,185 shares on October 22 under a pre-arranged 10b5-1 plan, a scheduled disposal rather than a discretionary signal.
The October 30 print will test whether the recent 18% rally was justified by an improvement in product revenue and pipeline momentum, or whether the stock has simply run ahead of a fundamental story that has not yet turned.
Stocks in this article
See the live data behind this article on ORTEX.
Open CHKP on ORTEX →How this article was generated
- Generated
- 29 Oct 2026, 04:34
- Data as of
- 29 Oct 2026, 04:08
- Prompt version
- v1.0
- Data sources
- Short interestCost to borrowUtilizationOptions flowEarningsAnalyst consensusInstitutional positioningORTEX Alpha signalsRecent ORTEX notesAlt Data
ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.